CML Highlights of EHA 2025

Biological overview

Expert

Professor Tomasz Stokłosa
Head, Department of Tumor Biology and Genetics / Laboratory of Molecular Genetics and Cytogenetics, University Clinical Center
Medical University of Warsaw (Poland) 

Program

Overview of significant biological aspects presented during the meeting, including:

• Modeling stem cell dynamics in chronic myeloid leukemia (Richard van Etten) [04:18]
• Insights from single-cell analysis of CML stem cells (Göran Karlsson) [09:24]
• Early response prediction by single cell immune and signaling profiling in CML (Stein-Erik Gullaksen) [11:35]
• Impact of mitochondrial DNA mutations on metabolic adaptation and TKI response in CML (Ilaria Pagani) [14:00]
• Integrating genomic and transcriptomic factors for predicting responses and outcomes in CML on 3G-TKI therapy (Xiaoshuai Zhang) [15:42]
• SETD2 deficiency in CML induces metabolic reprogramming contributing to drug resistance and disease progression (Manuela Mancini) [16:24]
• Comprehensive molecular characterisation of treatment-free remission in CML patients - The EURO-SKI Biomarker Study (Sebastien Rinaldetti)[16:59]

Clinical overview

Expert

Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology
Jena University Hospital (Germany)
 

Program

Overview of significant clinical aspects presented during the meeting, including:

• 2025 European LeukemiaNet (ELN) recommendations for the management of CML (Jane Apperley on behalf of the ELN Consensus Panel) [01:15]
• Asciminib shows superior tolerability versus nilotinib in newly diagnosed CML in chronic-phase: Primary results of the Phase 3b ASC4START Trial (Andreas Hochhaus) [10:49]
• CML treatment discontinuation after a two-step dose reduction. First results of the phase 2 study HALF (Jiří Mayer) [13:04]
• ENABLE: A phase 1a/1b study of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated CML (Andreas Hochhaus) 15:19]
• Characterization and efficacy of TERN-701 in pre-clinical models of CML (Timothy Hughes) [18:00]
• Q&A Session (covering biological and clinical questions) [20:42]